Abstract
Although direct-acting antivirals (DAAs) have significantly increased the sustained virological response (SVR) rates in chronic hepatitis C virus (HCV)-infected adult patients, the efficacy and safety for children remain unclear. We herein report three HCV-infected children who received DAA treatment. The patients were girls 10-13 years old who had been infected with genotype 1b HCV by vertical transmission based on a phylogenetic tree analysis. Two patients were treated with 12 weeks of ombitasvir/paritaprevir/ritonavir, and the other patient was treated with 8 weeks of glecaprevir/pibrentasvir. All children received DAA doses that were similar to the dosages for adult patients. None developed adverse events, and all children achieved an SVR.
Keywords:
DAA; HCV; child.
MeSH terms
-
Adolescent
-
Aminoisobutyric Acids
-
Anilides / therapeutic use*
-
Antiviral Agents / therapeutic use*
-
Benzimidazoles / therapeutic use*
-
Carbamates / therapeutic use*
-
Child
-
Cyclopropanes
-
Drug Therapy, Combination
-
Female
-
Genotype
-
Hepacivirus / genetics*
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Lactams, Macrocyclic
-
Leucine / analogs & derivatives
-
Macrocyclic Compounds / therapeutic use*
-
Proline / analogs & derivatives
-
Pyrrolidines
-
Quinoxalines / therapeutic use*
-
Sulfonamides / therapeutic use*
-
Sustained Virologic Response
-
Treatment Outcome
-
Valine
Substances
-
Aminoisobutyric Acids
-
Anilides
-
Antiviral Agents
-
Benzimidazoles
-
Carbamates
-
Cyclopropanes
-
Lactams, Macrocyclic
-
Macrocyclic Compounds
-
Pyrrolidines
-
Quinoxalines
-
Sulfonamides
-
ombitasvir
-
pibrentasvir
-
Proline
-
Leucine
-
Valine
-
glecaprevir
-
paritaprevir